 |
|
|
|
 For more information please contact:
Richard Moyer
212.554.5466
richard@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar » |
|
Cytori Therapeutics (Nasdaq: CYTX)
Cytori develops and globally commercializes regenerative medicine technologies, which provide real-time, point-of-care access to clinical grade regenerative cells. Our technology is incorporated into two product families. The Celution(R)-related products are sold throughout Europe and Asia primarily into the cosmetic and reconstructive surgery market and are under evaluation by the U.S. FDA. Our StemSource(R) products are sold globally for cell banking and research applications. We are also developing additional clinical uses of our technology for the treatment of multiple medical conditions, including cardiovascular disease, urinary tract disorders, and wound related conditions. To commercialize our technology, Cytori has partnered with global and regional leaders in healthcare such as Olympus Corporation, GE Healthcare, and Green Hospital Supply.
|
January 27, 2010:
Cytori's StemSource(R) Cell Bank to Be Installed at Leading Cosmetic & Reconstructive Surgery Network in Japan
- download word.doc (40 Kb) »
|
January 26, 2010:
Cytori Issued U.S. Patent for Cell-Enriched Fat Grafting; New Patent Protects Key Cytori Market
- download word.doc (40 Kb) »
|
January 8, 2010:
FDA Grants 510(k) Marketing Clearance for Cytoris PureGraft System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts
- download word.doc (40 Kb) »
|
September 14, 2009:
Cytori Reports Preclinical Results that Suggest Adipose-Derived Regenerative Cells may Reverse Periodontal Disease
- download word.doc (40 Kb) »
|
August 10, 2009:
Cytori Reports 2nd Quarter 2009 Financial Results
- download word.doc (40 Kb) »
|
July 17, 2009:
Cytori?s Celution® 700 System to be Regulated as a Medical Device by U.S. FDA
- download word.doc (40 Kb) »
|
